Your browser doesn't support javascript.
loading
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Crespiatico, Ilaria; Zaghi, Mattia; Mastini, Cristina; D'Aliberti, Deborah; Mauri, Mario; Mercado, Carl Mirko; Fontana, Diletta; Spinelli, Silvia; Crippa, Valentina; Inzoli, Elena; Manghisi, Beatrice; Civettini, Ivan; Ramazzotti, Daniele; Sangiorgio, Valentina; Gengotti, Michele; Brambilla, Virginia; Aroldi, Andrea; Banfi, Federica; Barone, Cristiana; Orsenigo, Roberto; Riera, Ludovica; Riminucci, Mara; Corsi, Alessandro; Breccia, Massimo; Morotti, Alessandro; Cilloni, Daniela; Roccaro, Aldo; Sacco, Antonio; Stagno, Fabio; Serafini, Marta; Mottadelli, Federica; Cazzaniga, Giovanni; Pagni, Fabio; Chiarle, Roberto; Azzoni, Emanuele; Sessa, Alessandro; Gambacorti-Passerini, Carlo; Elli, Elena Maria; Mologni, Luca; Piazza, Rocco.
Afiliación
  • Crespiatico I; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Zaghi M; Neuroepigenetics Unit, Division of Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy.
  • Mastini C; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • D'Aliberti D; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Mauri M; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Mercado CM; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Fontana D; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Spinelli S; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Crippa V; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Inzoli E; Hematology Division and Bone Marrow Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy.
  • Manghisi B; Hematology Division and Bone Marrow Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy.
  • Civettini I; Hematology Division and Bone Marrow Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy.
  • Ramazzotti D; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Sangiorgio V; Hematology Division and Bone Marrow Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy.
  • Gengotti M; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Brambilla V; Department of Pathology, University of Milan-Bicocca, Monza, Italy.
  • Aroldi A; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Banfi F; Hematology Division and Bone Marrow Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy.
  • Barone C; Neuroepigenetics Unit, Division of Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy.
  • Orsenigo R; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Riera L; Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute, Vall d'Hebron Hospital Barcelona UAB, Barcelona, Spain.
  • Riminucci M; Department of Pathology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Turin, Italy.
  • Corsi A; Department of Molecular Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
  • Breccia M; Department of Molecular Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
  • Morotti A; Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
  • Cilloni D; Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy.
  • Roccaro A; Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy.
  • Sacco A; Clinical Trial Center, Translational Research and Phase I Unit, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy.
  • Stagno F; Clinical Trial Center, Translational Research and Phase I Unit, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy.
  • Serafini M; Division of Hematology, Azienda Ospedaliero Universitaria Policlinico G. Rodolico-S. Marco, Catania, Italy.
  • Mottadelli F; Centro Tettamanti, Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy.
  • Cazzaniga G; Centro Tettamanti, Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy.
  • Pagni F; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Chiarle R; Centro Tettamanti, Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy.
  • Azzoni E; Department of Pathology, University of Milan-Bicocca, Monza, Italy.
  • Sessa A; Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy.
  • Gambacorti-Passerini C; Department of Pathology, Children's Hospital and Harvard Medical School, Boston, MA.
  • Elli EM; European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico, Division of Haematopathology, Milan, Italy.
  • Mologni L; Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
  • Piazza R; Neuroepigenetics Unit, Division of Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy.
Blood ; 143(14): 1399-1413, 2024 Apr 04.
Article en En | MEDLINE | ID: mdl-38194688
ABSTRACT
ABSTRACT SETBP1 mutations are found in various clonal myeloid disorders. However, it is unclear whether they can initiate leukemia, because SETBP1 mutations typically appear as later events during oncogenesis. To answer this question, we generated a mouse model expressing mutated SETBP1 in hematopoietic tissue this model showed profound alterations in the differentiation program of hematopoietic progenitors and developed a myeloid neoplasm with megakaryocytic dysplasia, splenomegaly, and bone marrow fibrosis, prompting us to investigate SETBP1 mutations in a cohort of 36 triple-negative primary myelofibrosis (TN-PMF) cases. We identified 2 distinct subgroups, one carrying SETBP1 mutations and the other completely devoid of somatic variants. Clinically, a striking difference in disease aggressiveness was noted, with patients with SETBP1 mutation showing a much worse clinical course. In contrast to myelodysplastic/myeloproliferative neoplasms, in which SETBP1 mutations are mostly found as a late clonal event, single-cell clonal hierarchy reconstruction in 3 patients with TN-PMF from our cohort revealed SETBP1 to be a very early event, suggesting that the phenotype of the different SETBP1+ disorders may be shaped by the opposite hierarchy of the same clonal SETBP1 variants.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Mielodisplásicas-Mieloproliferativas / Mielofibrosis Primaria / Sistema Hematopoyético / Trastornos Mieloproliferativos Límite: Animals / Humans Idioma: En Revista: Blood Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Mielodisplásicas-Mieloproliferativas / Mielofibrosis Primaria / Sistema Hematopoyético / Trastornos Mieloproliferativos Límite: Animals / Humans Idioma: En Revista: Blood Año: 2024 Tipo del documento: Article País de afiliación: Italia